For the Inventor, By the Inventor

Enter assignee name

Durham, NC, United States of America

Precision Biosciences, Inc.

USPTO Granted Patents = 56

% Expired Patents = 1.8

EPO Patents = 43

Trademarks = 4

Forward Citations = 273

Loading Chart...

Loading Chart...

29 inventors (with patents filed for the assignee):

James Jefferson Smith (47 out of 67 patents)

Derek Jantz (41 out of 59 patents)

Victor Bartsevich (20 out of 20 patents)

4. Michael G Nicholson (18 out of 19 patents)

5. Daniel T MacLeod (14 out of 14 patents)

6. Jeyaraj Antony (12 out of 12 patents)

7. Janel Lape (12 out of 12 patents)

8. Aaron Martin (8 out of 8 patents)

9. John K Morris (6 out of 37 patents)

10. Clayton Beard (5 out of 5 patents)

11. Jon E Chatterton (5 out of 5 patents)

12. Hui Li (4 out of 4 patents)

13. Gary Owens (4 out of 4 patents)

14. Michelle Brenda Pires (3 out of 3 patents)

15. Caitlin Turner (3 out of 3 patents)

Core Competencies:

Engineered Meganucleases

Gene Editing

Hemophilia

Retinitis Pigmentosa

Polynucleotides

Genetically-modified Cells

T Cell Receptor

Hepatitis B Virus

Alpha-1 Antitrypsin

Muscle-specific Expression

Nucleic Acid Molecules

56 patents: Sort by Forward Citations

1. 12752019 - ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HYDROXYACID OXIDASE 1 GENE (2026-10-06),

2. 12747430 - ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE TRANSTHYRETIN GENE (2026-09-29),

3. 12697400 - GENE EDITING METHODS FOR TREATING ALPHA-1 ANTITRYPSIN (AAT) DEFICIENCY (2026-08-04),

4. 12668818 - MUSCLE-SPECIFIC EXPRESSION CASSETTES (2026-06-30),

5. 12655407 - ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME (2026-06-16),

6. 12644135 - POLYPEPTIDE LINKERS FOR USE IN ENGINEERED MEGANUCLEASES (2026-06-02),

7. 12595470 - ENGINEERED NUCLEASES THAT TARGET HUMAN AND CANINE FACTOR VIII GENES AS A TREATMENT FOR HEMOPHILIA A (2026-04-07),

8. 12595469 - TREATMENT OF RETINITIS PIGMENTOSA USING IMPROVED ENGINEERED MEGANUCLEASES (2026-04-07),

9. 12448613 - Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene (2025-10-21),

10. 12410418 - Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome (2025-09-09),

11. 12351839 - Rationally-designed single-chain meganucleases with non-palindromic recognition sequences (2025-07-08),

12. 12006522 - Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene (2024-06-11),

13. 11993793 - Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene (2024-05-28),

14. 11866747 - Engineered meganucleases that target human mitochondrial genomes (2024-01-09),

15. 11851680 - Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR) (2023-12-26),

Precision Biosciences, Inc. is a biotechnology company based in Durham, North Carolina, specializing in gene editing technologies. The company focuses on developing engineered meganucleases and other innovative approaches to gene editing, targeting conditions such as hemophilia and retinitis pigmentosa. Precision Biosciences is also engaged in creating genetically-modified cells and advancing T cell receptor therapies, with applications in treating various diseases, including hepatitis B virus infections.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Precision Biosciences, Inc.

56 Patents

#20 in Durham, NC

#153 in North Carolina

#6,354 in US

#12,744 in the World

Durham, NC, United States of America

Precision Biosciences, Inc.

Forward Citations = 273

29 inventors:

James Jefferson Smith (47 out of 67 patents)

Derek Jantz (41 out of 59 patents)

Victor Bartsevich (20 out of 20 patents)

4. Michael G Nicholson (18 out of 19 patents)

5. Daniel T MacLeod (14 out of 14 patents)

Please report any incorrect information to [email protected]

Loading…